(Q35953306)

11 August 2017

1 reference

title

Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors (English)

1 reference

11 August 2017

Douglas S Goodin

1

1 reference

11 August 2017

language of work or name

1 reference

1 September 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

251 Suppl 5

1 reference

11 August 2017

page(s)

v3-v11

1 reference

https://scigraph.springernature.com/pub.10.1007/s00415-004-1503-z

11 August 2017

exact match

0 references

cites work

Significance questing

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-004-1503-Z

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-004-1503-Z

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00415-004-1503-Z

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

21 January 2018

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

p values, hypothesis tests, and likelihood: implications for epidemiology of a neglected historical debate.

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis

1 reference

12 December 2020

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

1 reference

12 December 2020

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study

1 reference

12 December 2020

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

1 reference

12 December 2020

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

1 reference

12 December 2020

Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

More powerful procedures for multiple significance testing

1 reference

12 December 2020

Procedures for comparing samples with multiple endpoints

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

1 reference

12 December 2020

The problem of multiple inference in studies designed to generate hypotheses

1 reference

12 December 2020

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

12 December 2020

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

Stressful life events precede exacerbations of multiple sclerosis

1 reference

12 December 2020

Design, methods, and conduct of the Optic Neuritis Treatment Trial

1 reference

12 December 2020

Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis

1 reference

12 December 2020

Applications of global statistics in analysing quality of life data

1 reference

12 December 2020

10.1007/S00415-004-1503-Z

Identifiers

DOI

1 reference

11 August 2017

1 reference